Perrigo Company plc Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Perrigo Company plc on April 26, 2019. The filing addresses a significant tax-related development involving a revised Notice of Proposed Adjustment (NOPA) received from the U.S. Internal Revenue Service (IRS) regarding the Company's former subsidiary, Athena Neurosciences, Inc. (Athena), for tax years 2011 through 2013.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or margins for the current period. The primary financial figure disclosed is a proposed tax liability:
- Proposed Tax and Penalty: $843 million (comprising additional tax and a 40% penalty).
- Exclusions: This amount excludes offsetting tax attributes and potentially material interest.
- Liquidity Impact: Management states no payment is currently required and does not anticipate a material adverse impact on liquidity unless a final adverse determination is reached.
Material Changes and Developments
The material change reported is the receipt of a revised NOPA from the IRS, superseding a draft NOPA received in July 2017. The IRS asserts that Elan Corporation, plc (acquired by Perrigo in 2013) owed Athena additional royalty income related to the drug Tysabri prior to the 1996 acquisition of Athena by Elan. The IRS proposes a theoretical 24.7% license royalty rate applied to Tysabri sales revenue. Perrigo strongly disagrees with this position, maintaining that the original transfer pricing methodology was appropriate and that no penalty should apply.
Outlook, Risks, and Management Commentary
Management intends to pursue all available administrative and judicial remedies, including potential relief under the U.S.-Ireland Income Tax Treaty to alleviate double taxation, as the income in question was already reported in Ireland. While the Company believes its position is correct, it acknowledges there can be no assurance of a favorable outcome. An unfavorable resolution could materially adversely impact liquidity and capital resources. The Company does not expect this development to materially impact its financial statements at this time, noting that resolution could take several years.
Forward-looking statements in the filing highlight risks including the resolution of uncertain tax positions, potential litigation related to financial restatements, and the impact of tax reform legislation.
Investor Verification Checklist
- Verify the status of the IRS audit and the timeline for administrative or judicial resolution of the $843 million NOPA.
- Review the Company's assessment of offsetting tax attributes that could reduce the proposed liability.
- Monitor updates regarding the parallel Notice of Assessment (NoA) issued by the Irish Office of the Revenue Commissioners.
- Assess the potential impact of the proposed tax liability on future cash flows if the Company's legal defense is unsuccessful.
- Check for any subsequent filings regarding the separation of the RX business and its interaction with these tax contingencies.